1. Home
  2. NTWK vs SCYX Comparison

NTWK vs SCYX Comparison

Compare NTWK & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetSol Technologies Inc.

NTWK

NetSol Technologies Inc.

HOLD

Current Price

$4.08

Market Cap

50.6M

Sector

Technology

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$5.30

Market Cap

51.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTWK
SCYX
Founded
1997
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.6M
51.4M
IPO Year
1997
2014

Fundamental Metrics

Financial Performance
Metric
NTWK
SCYX
Price
$4.08
$5.30
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
15.4K
79.9K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
316.67
61.36
EPS
N/A
N/A
Revenue
$73,088,687.00
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
13.40
N/A
52 Week Low
$2.73
$0.57
52 Week High
$5.75
$6.09

Technical Indicators

Market Signals
Indicator
NTWK
SCYX
Relative Strength Index (RSI) 48.21 57.42
Support Level $2.94 $4.65
Resistance Level $4.53 $5.56
Average True Range (ATR) 0.11 0.36
MACD 0.01 -0.04
Stochastic Oscillator 58.37 34.45

Price Performance

Historical Comparison
NTWK
SCYX

About NTWK NetSol Technologies Inc.

NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: